QCG
TARS icon

Quadrant Capital Group’s Tarsus Pharmaceuticals TARS Stock Holding History

Quadrant Capital Group’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$421 – 2436
2026
Q1 		$421 Hold
6
– – ﹤0.01% 2636
2025
Q4 		$492 Hold
6
– – ﹤0.01% 2650
2025
Q3 		$357 Buy
+6
New +$295 ﹤0.01% 2633
2025
Q2 		– Sell
-89
Closed -$4.57K – 2482
2025
Q1 		$4.57K Hold
89
– – ﹤0.01% 2374
2024
Q4 		$4.93K Buy
89
+83
+1,383% +$3.77K ﹤0.01% 2302
2024
Q3 		$198 Buy
+6
New +$169 ﹤0.01% 2709
2023
Q4 		– Sell
-130
Closed -$2.31K – 2783
2023
Q3 		$2.31K Buy
+130
New +$2.3K ﹤0.01% 2356

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Quadrant Capital Group's TARS Position: Q2 2026 in Review

Quadrant Capital Group sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 6 shares — an estimated $421 sold.

Quadrant Capital Group first reported a position in TARS in Q3 2023 and held it in 7 quarters. The position peaked at $4.93K in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Quadrant Capital Group reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 6 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $421.
  • Quadrant Capital Group first reported a position in Tarsus Pharmaceuticals in Q3 2023 and held it in 7 quarters.
  • Quadrant Capital Group's Tarsus Pharmaceuticals position peaked at $4.93K in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.